Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.

Freenome has announced a strategic agreement with Roche aimed at commercialising its cancer screening technology outside the ...

Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a ...

Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening ...